Abstract. It has been proposed that neuroinflammation, among other factors, may trigger an aberrant neuronal cell cycle re-entry leading to neuronal death. Cell cycle disturbances are also detectable in peripheral cells from Alzheimers disease (AD) patients. We previously reported that the anti-inflammatory 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ) increased the cellular content of the cyclin-dependent kinase inhibitor p27, in lymphoblasts from AD patients. This work aimed at elucidating the mechanisms of 15d-PGJ 2 -induced p27 accumulation. Phosphorylation, half-life, and the nucleo-cytoplasmic traffic of p27 protein were altered by 15d-PGJ 2 by mechanisms dependent on PI3K/Akt activity. 15d-PGJ 2 prevents the calmodulin-dependent Akt overactivation in AD lymphoblasts by blocking its binding to the 85-kDa regulatory subunit of PI3K. These effects of 15d-PGJ 2 were not mimicked by 9,10-dihydro-15-deoxy-D 12,14 -prostaglandin J 2 , suggesting that 15d-PGJ 2 acts independently of peroxisome proliferator-activated receptor g activation and that the a,b-unsaturated carbonyl group in the cyclopentenone ring of 15d-PGJ 2 is a requisite for the observed effects.
Introduction
Alzheimers disease (AD) is a complex disorder afflicting the rapidly growing elderly segment of todays population, for which the current therapeutic tools offer only moderate symptomatic relief.
The AD brain pathophysiology includes not only the deposition of amyloid-b-protein, and neurofibrillary tangles but also, among other aspects, signs of chronic inflammation associated with significant neuronal loss [1] . Epidemiological studies have shown that longterm use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset [2] . NSAIDs are known as ligands for the peroxisome proliferator-activated receptor g (PPAR g) [3] , and it is believed that some of their effects are exerted through the activation of this transcription factor. Several natural and synthetic ligands for PPARg have been described, among them, 15-deoxy-D 12, 14 -prostaglandin J 2 (15d-PGJ 2 ), a prostaglandin J 2 metabolite, has been shown to be the most potent activator. 15d-PGJ 2 is known to increase in the course of inflammatory processes [4] . 15d-PGJ 2 displays anti-inflammatory and protective effects against certain types of injury in cellular systems, animal models and humans [5] [6] [7] . In addition to these effects, 15d-PGJ 2 has been shown to induce cell growth arrest and apoptosis in several cancer cell types [8, 9] . Research over the last decade has revealed that cell cycle-related events occur in susceptible neurons during AD, and that they are followed by apoptotic cell death [10] [11] [12] . Thus, understanding the molecular pathways underlying this cell cycle-mediated neurodegeneration may be important to find new therapeutic targets to slow or prevent the onset and progression of AD [13] . Several factors, including neuroinflammation can trigger aberrant neuronal cell cycle reentry [14] . Therefore, it was hypothesized that the protective effects of NSAIDs in AD could be due not only to their ability to down-regulate the proinflammatory cytokines released by microglia, but also to their anti-proliferative effects [15, 16] . Numerous observations indicate that, while the predominant clinical expression arises from brain pathology, AD has systemic expression at the cellular and molecular levels [17, 18] . Although these alterations appear to have no consequences outside the central nervous system, their parallel expression in the brain could be considered a plausible pathophysiological model to explain partly the clinical manifestations. Of particular relevance to this work is the fact that cell cycle abnormalities are also found in peripheral cells from AD patients [19, 20] . Epstein Barr virus (EBV) infection in vitro causes transformation of B cells and generates B lymphoblastoid cell lines (LCLs) [21] . These LCLs retain the phenotype and functions of mature B cells [22] . LCLs have been widely used as models in various biological and medical studies [23] . Previous work from this laboratory, using EBV-immortalized lymphocytes from late-onset AD patients, demonstrated a Ca 2+ / calmodulin (CaM)-dependent stimulation of cell proliferation and survival of AD lymphoblasts compared with age-matched non-demented donors [24, 25] . Moreover, we reported that immortalization of peripheral lymphocytes from AD patients with the Epstein Barr virus do not alter the cellular response to serum addition or withdrawal [26, 27] . These observations indicate that established lymphoblastoid cell lines could be a suitable model to study the influence of cell cycle-related events in the pathogenesis of AD. We have previously reported that 15d-PGJ 2 inhibited the serum-enhanced cell proliferation of lymphoblasts from AD patients, by blocking the critical events for G 1 /S transition [28] . The cyclopentenone partially inhibited phosphorylation of retinoblastoma protein (pRb) and up-regulated the levels of the cyclindependent kinase (CDK) inhibitor p27. This work was undertaken to further study the mechanism(s) involved in 15d-PGJ 2 -induced increased levels of p27 protein in AD lymphoblasts. Our results suggest that 15d-PGJ 2 blockade of Ca 2+ /CaM-mediated overactivation of PI3K/Akt in AD cells is an important part of the mechanism by which the cyclopentenone regulates the expression levels of p27 and cell cycle progression in AD lymphoblasts. We report here that 15d-PGJ 2 appears to impair the binding of CaM to the p85 regulatory subunit of PI3K, thereby decreasing PI3K/ Akt activation. This effect of the cyclopentenone results in reduced phosphorylation and degradation, as well as nuclear retention of p27 protein.
Materials and methods

Materials
All components for cell culture were obtained from Invitrogen (Carlsbad, CA). The kinases inhibitors Ly294002, SP600125, PD98059, and 15d-PGJ 2 were obtained from Calbiochem (Darmstadt, Germany). 9,10-Dihydro-15d-PGJ 2 was from Cayman Chemical (Ann Arbor, MI). Radioactive compounds were purchased from Amersham (Uppsala, Sweden). Polyvinylidene fluoride (PVDF) membranes for Western blots were purchased from Bio-Rad (Richmond, CA). Rabbit polyclonal antibodies (pAbs) against human phospho-Akt (Ser473), phospho-ERK1/2, total ERK1/2 and total JNK were obtained from Cell Signaling (Beverly, MA) and phospho-JNK was from Promega (Fitchbury, WI). Mouse monoclonal antibody anti-human lamin B1 (sc-20682) and anti-human PI3K p85a (sc-1637) and pAbs such as rabbit anti-human p27 (sc-528), rabbit anti-human phospho-p27 (Thr187) (sc-16324-R), rabbit anti-human CDK2 (sc-748), rabbit antihuman ubiquitin (sc-913), rabbit anti-human pRb (sc-50), rabbit anti-human SKP2 (sc-7164), rabbit anti-human CaM I (FL-149) and goat anti-human total-Akt (sc-1618) were from Santa Cruz Biotechnologies (Santa Cruz, CA). The enhanced chemiluminescence (ECL) system was from Amersham. MG132 and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] , histone H1, anti-bactin, anti-a-tubulin antibodies were obtained from Establishment of LCLs was performed in our laboratory as previously described [29] by infecting peripheral blood lymphocytes with the EBV [30] . Cells were grown in suspension in T flasks in an upright position, in approximately 10 ml RPMI 1640 (Gibco, BRL) medium that contained 2 mM Lglutamine, 100 mg/ml penicillin/streptomycin and, unless otherwise stated, 10 % (v/v) fetal bovine serum (FBS) and maintained in a humidified 5 % CO 2 incubator at 378C. Fluid was routinely changed every 2 days by removing the medium above the settled cells and replacing it with an equal volume of fresh medium.
Determination of cell proliferation
Proliferation was determined either by cell counting in a Neubauer chamber, or by using the MTT assay. This assay is based on the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide by mitochondrial dehydrogenase in viable cells [31] . Potential toxicity of the reagents used was routinely checked by trypan blue exclusion under inverted phase-contrast microscopy.
Cell cycle analysis
Exponentially growing cultures of cell lines were seeded at an initial concentration of 110 6 cells/ml. Cell cycle analysis was performed using a standard method [32] . Cells were fixed in 75 % ethanol for 1 h at room temperature. Subsequent centrifugation of the samples was followed by incubation of cells in PBS containing 1 mg/ml of RNase at room temperature for 20 min and staining with propidium iodide (PI; 25 mg/ ml). Cells were analyzed in an EPICS-XL cytofluorimeter (Coulter Científica, Móstoles, Spain). Estimates of cell cycle phase distributions were obtained by computer analysis of DNA content distributions.
Proteasome activity assay
The proteasome activity assay was performed in total cell extracts from control and AD lymphoblasts incubated in the absence or in the presence of 1 mM MG132 for 24 h. To measure the proteasome chymotrypsin peptidase activity, 10 mg protein extract was mixed with 300 ml reaction buffer containing 20 mM HEPES, 0.5 mM EDTA pH 8.0, 0.035 % SDS, and 20 mM succinyl-Leu-Leu-Val-Try-7-amido-4-methylcoumarin at 378C for 90 min. Substrate hydrolysis was measured by monitoring the release of Try-7-amido-4-methylcoumarin using a spectrofluorometer (excitation at 370 nm, emission at 460 nm) as described [33] .
Immunological analysis
Cell extracts. To prepare whole cell extracts, cells were harvested, washed in PBS and then lysed in ice-cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 50 mM NaF, 1 % Nonidet P-40), containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate and protease inhibitor Complete Mini Mixture (Roche, Mannheim). Cytosolic and nuclear proteins were differentially extracted by lysing cells in ice-cold hypotonic buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphatase, and protease inhibitor mixture. After extraction on ice for 15 min, 0.5 % Nonidet P-40 was added, and the lysed cells centrifuged at 4000 rpm for 10 min. Supernatants containing cytosolic proteins were centrifuged at 13 000 rpm for 10 min. Nuclei were washed twice with the hypotonic buffer, and then lysed in hypertonic buffer (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT) containing 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM sodium pyrophosphate and protease inhibitor mixture. After extraction on ice for 30 min, the samples were centrifuged at 15 000 rpm for 15 min at 48C. Antibodies to a-tubulin and to lamin B1 were used to assess the purity of the fractions. The protein content of the extracts was determined by the Bio-Rad protein assay kit (Bio-Rad Laboratories).
Western blot analysis. From the whole cell extracts, 50 -100-mg samples were fractionated on a SDSpolyacrylamide gel, and transferred to PVDF membrane (Immobilon-P). The amount of protein and the integrity of transfer were verified by staining with Ponceau-S solution (Sigma). The filters were then blocked with non-fat milk and incubated, overnight at 48C, with primary antibodies at the following dilutions: 1:500 anti-p27, 1:500 anti-phospho p27, 1:1000 anti-SKP2, 1:500 anti-ubiquitin, 1:1000 anti-phospho Akt, 1:1000 anti-Akt, 1:2000 anti-b-actin, 1:2000 antia-tubulin and 1:1000 anti-lamin B1. Signals from the primary antibodies were amplified using speciesspecific antisera conjugated with horseradish peroxidase (Sigma) and detected with a chemiluminescent substrate detection system ECL (Amersham). Blots were stripped and reprobed with anti-b-actin as a protein-loading control. The relative protein levels were determined by scanning the bands with a GS-800 imaging densitometer provided with the Quantity One 4.3.1. software from Bio-Rad, normalized by that of b-actin.
Immunoprecipitation and cyclin E/CDK2 kinase assay Lymphoblasts from control and AD individuals were seeded at an initial cell density of 110 6 cells/ml and incubated for 24 h. Protein extracts (500 mg) were incubated with an antibody against CDK2 for 2 h at 48C, followed by an incubation with 20 ml protein GSepharose for 2 h. Samples were washed in kinase buffer (50 mM KCl, 8 mM MgCl 2 , 1 mM DTT, 3 mM ATP, 50 mM HEPES, pH 7.4). The immune complexes were resuspended in 40 ml kinase buffer containing histone H1 (0.2 mg/ml). [g-32 P]ATP (10 mCi) was added, and after shaking for 1 h at 378C, the reaction was stopped by addition of 10 ml 6 SDS sample buffer. After boiling, the samples were resolved by SDS-PAGE on a 12 % gel and the phosphorylated histone H1 was visualized by autoradiography. The amounts of histone H1 were detected by gel staining with Coomassie.
Co-immunoprecipitation assays
Lymphoblasts from AD individuals were seeded at an initial cell density of 110 6 cells/ml and incubated for 24 h. Protein extracts (600 mg) were subjected to immunoprecipitation overnight at 48C with an antip85 monoclonal antibody in the presence of 0.1 mM CaCl 2 or 2 mM EGTA. Samples were incubated then with protein G for 2 h at 48C. Immunocomplexes were washed three times with ice-cold lysis buffer containing CaCl 2 or EGTA, suspended with sample buffer, boiled, resolved by SDS-PAGE, and transferred onto PVDF Immobilon-P transfer membrane filters. Blots were probed with an anti-CaM pAb. Membranes were reprobed with the anti-p85 antibody to check for equal immunoprecipitation efficiency.
Confocal laser scanning microscopy
Lymphoblasts from AD individuals were seeded at an initial density of 110 6 cells/ml and incubated for 24 h in the absence or in the presence of 2.5 mM 15d-PGJ 2 . Cells were harvested, washed in PBS and fixed in freshly prepared 4 % paraformaldehyde in PBS for 30 min at room temperature. After two washes with PBS containing 3 mg/ml BSA, cells (approximately 10 000) were plated onto 0.1 % poly-L-lysine-coated glass slides and allowed to adhere by spinning at 700 rpm for 7 min. Cells were permeabilized and blocked with PBS containing 0.2 % Triton X-100 and 10 % normal goat serum (NGS) for 1 h. Cells were incubated overnight with anti-p27 (1:50), washed, and incubated with Alexa Fluor 488-conjugated secondary antibody (1:200) for 1 h at room temperature. Samples were subsequently washed three times in PBS and mounted in Vectashield
Mounting Medium with DAPI (Vector Labs, UK) and visualized on confocal microscope (Leica DMRE2, Heidelberg, Germany).
Statistical analysis
Unless otherwise stated, all data represent means AE SE. Statistical analysis was performed on the Data Desk package (version 4.0) for Macintosh. Statistical significance was estimated by the Students t-test or, when appropriated, by analysis of variance (ANOVA) followed by the Fischers LSD test for multiple comparisons. Differences were considered significant at a level of p < 0.05.
Results
Effects of 15d-PGJ 2 on cell proliferation It was previously reported that 15d-PGJ 2 has an antiproliferative effect on lymphoblasts from AD patients associated with altered control of G 1 /S transition and accumulation of p27 protein [28] . For this reason, we first tried to elucidate the effects of 15d-PGJ 2 treatment on the phosphorylation status of the pRb and on the kinase activity of cyclin E/CDK2 complex, the key regulators of transition from G 1 phase of the cell cycle to S phase. Figure 1A shows a time course analysis of the effect of 15d-PGJ 2 on rates of proliferation of control and AD lymphoblasts following serum stimulation. It is shown, in agreement with previous results [28] , that AD cells proliferate at a higher rate than control cells (Fig. 1A) . Addition of 15d-PGJ 2 had no effect on control cells, but significantly reduced the enhanced proliferative activity of AD cells (Fig. 1A) . The effect of 15d-PGJ 2 reducing total cell number in AD cultures is not due to increased cell death. A comparative analysis, by flow cytometry, of cell cycle status of control and AD cells following treatment 3510 Ú. MuÇoz et al. Up-regulation of p27 kip1 in Alzheimers disease with 15d-PGJ 2 revealed that at the concentration of the drug used, there was no evidence of apoptosis/ necrosis in either control or AD cell lines, since a subdiploid pre G 0 /G 1 peak was not detected (not shown). As expected, the 15d-PGJ 2 -induced inhibition of cell proliferation was accompanied by an accumulation of the CDKi p27 (Fig. 1B) . 15d-PGJ 2 inhibited the serum-mediated enhanced cyclin E/ CDK2-associated kinase activity in AD cells, and partially blocked pRb phosphorylation (Fig. 1C) . Figure 2A shows that the effect of 15d-PGJ 2 inhibiting cell proliferation in AD lymphoblasts is reversible. For these experiments, lymphoblasts from AD patients were incubated in the absence and in the presence of 15d-PGJ 2 for 24 h, then, the medium was changed and cells were enumerated every day. After 15d-PGJ 2 removal, the kinetics of cell proliferation was back to normal ( Fig. 2A) . As shown in Figure 2B , p27 levels decreased progressively, returning to basal levels following 15d-PGJ 2 withdrawal.
p27 accumulation is due to increased protein half-life in 15d-PGJ 2 -treated cells To determine if the increase in p27 protein following 15d-PGJ 2 treatment resulted from altered protein half-life, AD cells were incubated with and without 15d-PGJ 2 for 24 h at which time cells were treated with cycloheximide to block de novo protein synthesis. p27 levels were then determined by Western blot analysis in cells harvested at various time points after Effects of 15d-PGJ 2 on p27 degradation We next investigated whether the 15d-PGJ 2 -mediated up-regulation of p27 protein in AD lymphoblasts was due to altered degradation of p27 protein, a process thought to take place in the proteasome [34] . p27 proteolysis is a three-step process that requires phosphorylation at Thr187, recognition by the F-box protein SKP2, ubiquitylation, and degradation by the 26S proteasome [34] . Figure 4 shows that 15d-PGJ 2 did not change the phosphorylation status of p27 in control cells, but abrogates the serum-induced increased levels of phospho-p27 (Thr187) in AD cells.
There is a tight inverse relationship between levels of phospho-p27 and expression levels (Fig. 4) . 15d-PGJ 2 treatment had no effect on the SKP2 content in either control or AD lymphoblasts. In addition, we did not find significant differences in the accumulation of ubiquitin-tagged proteins or in total proteasome activity between treated or untreated cells from control and AD patients (Fig. 5) . Therefore, these results suggest that, by inhibiting cyclin E/CDK2 kinase activity, and decreasing Thr187 phosphorylation of p27, 15d-PGJ 2 abrogates targeting of SCFubiquitin E3 ligase and minimizes proteasome degradation of p27, thus increasing cellular content of p27.
Effects of 15d-PGJ 2 on PI3K/Akt-mediated down-regulation of p27 in AD lymphoblasts
We have shown previously [26] that serum-mediated enhanced cell proliferation, and decreased levels of p27 in AD cells, requires the activation of PI3K/Akt signaling pathway. Here, we show that the specific inhibitor of PI3K/Akt, Ly294002 mimicked the effects of 15d-PGJ 2 inhibiting cell proliferation and increasing the p27 content of AD cells ( Fig. 6A and B) . When cells were treated with Ly294002 and 15d-PGJ 2 at the same time, no further inhibition of cell growth nor increase of p27 were observed ( Fig. 6A and B) , suggesting no additive effects of these two drugs. In contrast to 15d-PGJ 2 , the treatment of control cells with Ly294002 inhibited cell proliferation and increased the cellular content of p27 ( Fig. 6A and B) . The role of 15d-PGJ 2 on PI3K/Akt signaling pathway in control and AD lymphoblasts was assessed by monitoring the phosphorylation status of Akt, before and after 15d-PGJ 2 treatment, by Western blotting with a phospho-specific anti-Akt antibody. Figure 6C shows significant higher levels of phospho-Akt (Ser473) in AD cells compared with cells from age- Lymphoblasts from AD patients were incubated in triplicate in 24-well plates (210 6 /well) in the absence or in the presence of 2.5 mM 15d-PGJ 2 for 24 h; the medium was then changed and cells were enumerated every day thereafter. 15d-PGJ 2 was kept in one of the wells as control. Data shown are the mean AE SE for four independent experiments. (B) Lymphoblasts from AD patients were incubated in the presence of 2.5 mM 15d-PGJ 2 for 24 h. After replacing the medium, cells were cultured for an additional period of 24 h. Cells were harvested at the time points indicated in the figure and p27 was detected by immunoblotting. A representative experiment is shown. Figure 3 . Effect of 15d-PGJ 2 on the half-life of p27 protein in AD lymphoblasts. Lymphoblasts from AD subjects were incubated for 24 h in RPMI medium containing 10 % FBS, in the absence or in the presence of 2.5 mM 15d-PGJ 2 and then cycloheximide (10 mg/ml) was added. Cells were harvested 4, 8, and 24 h thereafter and p27 was detected by immunoblotting. The decay of the p27 signal is shown as a function of time post-cycloheximide addition. Linear regression curves were fitted to calculate the half-life of the protein using data from four different experiments. (Fig. 6C) . These results suggest that 15d-PGJ 2 prevents, rather than inhibits, overactivation of PI3K/Akt pathway in AD cells. Figure 6D shows that 15d-PGJ 2 did not affect either ERK1/2 or JNK activation in lymphoblasts from AD patients. It has been shown that PI3K/Akt may also contribute to regulation of p27 content by altering the nucleocytoplasmic traffic of the protein [35, 36] . For these reasons, we studied whether 15d-PGJ 2 treatment induced changes in the subcellular localization of p27 in AD cells. To this end, AD lymphoblasts were incubated with either 15d-PGJ 2 or Ly294002 and either fractionated to enrich for nuclear or cytoplasmic proteins or processed for immunostaining and confocal laser scanning microscopy. The Western blotting analysis of cytoplasmic and nuclear proteins revealed that 15d-PGJ 2 induced an increase in the nuclear p27 content (Fig. 7A) . Similar results were found when AD cells were treated with the PI3K/Akt inhibitor Ly294002 (Fig. 7A) . The results of protein fractionation and immunoblotting were consistent with the effects of 15d-PGJ 2 in the localization of p27 determined by immunostaining (Fig. 7B) .
Effects of 15d-PGJ 2 on interaction of CaM and PI3K
The fact that 15d-PGJ 2 affects neither Akt phosphorylation nor p27 content in control cells suggests that the cyclopentenone is acting upstream of Akt. 15d-PGJ 2 somehow prevents the serum-mediated enhanced PI3K/Akt pathway in AD cells. Overactivation of PI3K/Akt signaling pathway in AD cells depends on Ca 2+ /CaM [26] . Moreover, it had been reported that CaM is able to associate with SH 2 domains in the 85-kDa regulatory subunit of PI3K (p85), thereby activating PI3K in vitro, and in intact cells [37, 38] . For this reason, we next explored whether 15d-PGJ 2 is able to blunt the potential interaction between PI3K and CaM. To this end, cell lysates from AD lymphoblasts were immunoprecipitated with the anti-p85 antibody. The immunoprecipitates were analyzed by Western blot, and the immunoblots were probed with an anti-CaM antibody. CaM was found to co-immunoprecipitate with p85 (Fig. 8A) . As previously described [38] , CaM and p85 interaction was found to be Ca 2+ dependent (Fig. 8A ). When 15d-PGJ 2 was added during the immunoprecipitation process, the association was strongly reduced, Research Article 3513 indicating that 15d-PGJ 2 displaced CaM binding to PI3K in vitro (Fig. 8A) . Therefore, these results suggest that treatment of AD cells with 15d-PGJ 2 could prevent CaM-mediated activation of PI3K. The lack of effects of 15d-PGJ 2 in Akt phosphorylation in control cells suggest the existence of a threshold for CaM activation of PI3K. In consonance with this idea, we found increased expression levels of CaM in AD lymphoblasts compared with those observed in control cells (Fig. 8B) .
Effects of 15d-PGJ 2 preventing activation of PI3K/Akt and up-regulation of p27 protein are unlikely to be mediated by PPARg activation We previously reported [28] that the anti-proliferative effect of 15d-PGJ 2 in human lymphoblasts is not dependent on PPARg activation since it could not be blocked by the selective PPARg antagonist GW9662, and other PPARg ligands did not mimic the effect of 15d-PGJ 2 on proliferation of AD cells. Data in Figure 9 confirm and extend our previous finding, by showing that cell proliferation (Fig. 9A) , Akt phosphorylation and p27 levels are not affected in AD cells by 9,10-dihydro-15d-PGJ 2 , an analog of 15d-PGJ 2 that was designed to retain PPARg agonist activity and to be more resistant to metabolism [39] (Fig. 9B) . These results also indicate that the a,b-unsaturated carbonyl group in the cyclopentenone ring of 15d-PGJ 2 is a requisite for the effects of 15d-PGJ 2 in AD cells.
Discussion
Prostaglandins are small lipid molecules that regulate numerous processes in the body and their biological effects have been the subject of intense research in recent years. The 15d-PGJ 2 is the end-product metabolite of PGD 2 and it is produced by a variety of cells, including mast cells, T cells, platelets, alveolar macrophages, and activated microglia. In monocytes/macrophages, 15d-PGJ 2 exerts an anti-inflammatory action due to the attenuation of the expression of various proinflammatory genes such as IL-1 and TNF, and the expression of effectors proteins such as cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinases [40] [41] [42] . In addition, anti-neoplastic effects of 15d-PGJ 2 have been described in several cell types [8, 9] . Based on these observations, we hypothesized that the protective effects of antiinflammatory drugs on AD progression could be related to their ability to regulate cell cycle events. It was reported that 15d-PGJ 2 is able to selectively blunt the serum-enhanced proliferation of immortalized lymphocytes from late-onset AD patients without affecting normal proliferative response of control cells [28] . 15d-PGJ 2 inhibits cell cycle progression at the G 1 / S checkpoint in AD lymphoblasts [28] . Our results show that treatment of AD cells with 15d-PGJ 2 decreased the activity of the cyclin E/CDK2 complex, apparently by up-regulating the levels of the CDKi p27 and partially blocked the enhanced phosphorylation of pRb protein induced by serum stimulation in AD lymphoblasts. The anti-proliferative effect of 15d-PGJ 2 was shown to be independent of PPARg activation [28] . In agreement with this observation, we report here the effects of 15d-PGJ 2 are not mimicked by the analog 9,10-dihydro-15d-PGJ 2 that retains PPARg agonist activity. This finding also indicates that the a,b-unsaturated carbonyl group in the cyclopentenone ring is required for the effects of 15d-PGJ 2 in AD lymphoblasts. PPARg-independent effects of 15d-PGJ 2 have been previously reported in other cell types, including cells of the nervous system [43, 44] . Several mechanisms have been implicated as Research Article 3515 being responsible for the effects of 15d-PGJ 2 on the different cell types and these may partially explain its anti-neoplastic properties. Mediators of these actions include NF-kB inactivation [45] , AP1 [38] , reactive oxygen species [46] , and the MAPK or PI3K/Akt pathways [47, 48] . It has been reported that the PPARg-independent actions of 15d-PGJ 2 may be due to the reactive ring system [39] . Reduction of its double bound may impair significantly the ability of reacting covalently with nucleophile residues in cellular proteins. This study demonstrates that 15d-PGJ 2 blockade of PI3K/Akt overactivation is an important part of the mechanism by which the cyclopentenone regulates the expression levels of p27 and cell cycle progression in AD lymphoblasts. This asseveration finds support in the following observations: first, inhibition of PI3K/ Akt by Ly294002 had effects similar to those of 15d-PGJ 2 on p27 content and cell proliferation, and second 15d-PGJ 2 reduced Akt activation in AD lymphoblasts. Activation of PI3K/Akt pathway has been previously implicated in down-regulation of p27 levels in a number of cell types [49] [50] [51] The molecular mechanisms involved in PI3K/Akt-mediated p27 regulation are not completely understood, but include modulation of transcription, protein degradation and subcellular localization of p27. Our data reveal that levels of p27 were post-translationally up-regulated by 15d-PGJ 2 by decreasing the rate of p27 degradation in the ubiquitin-proteasome pathway. The half-life of p27 after 15d-PGJ 2 treatment of AD cells is considerably lengthened, approaching values observed in lymphoblasts from control individuals [26] . The 15d-PGJ 2 -mediated up-regulation of p27 protein correlated with inhibition of phosphorylation of p27 at Thr187 by the cyclin E/CDK2 complex, together with increased levels of p27 in the nucleus. The p27-specific F-box, protein SKP2, interacts with the C terminus of the phosphorylated protein in the cytosol. This association results in recruitment of p27 to the SCF core complex, thereby promoting its ubiquitination and degradation [52, 53] . Treatment of AD cells with 15d-PGJ 2 did not affect the expression levels of SKP2, the global proteasome activity or the accumulation of ubiquitin-tagged protein. These observations are in line with a recent report showing no differences in peripheral proteasome activity between control and AD lymphocytes [54] . The fact that 15d-PGJ 2 affects neither Akt phosphorylation nor p27 content in control cells suggests that the cyclopentenone is acting upstream of Akt. 15d-PGJ 2 somehow prevents the serum-mediated enhanced PI3K/Akt pathway in AD cells. We have recently reported that serum-mediated Akt activation in lymphoblasts from AD cells is Ca 2+ /CaM sensitive [26] . We report here that 15d-PGJ 2 is able to impair the binding of CaM to the 85-kDa regulatory subunit of PI3K (p85) in vitro. This mechanism could account for the decrease in Akt activation induced by 15d-PGJ 2 in AD cells, as it was previously demonstrated that CaM association with SH 2 domains in p85 leads to PI3K activation either in vitro or in intact cells [37, 38] . In addition, our results suggest the existence of a threshold for CaM to induce activation of PI3K/Akt pathway in human lymphocytes. In summary, the present work indicates that 15d-PGJ 2 is able to suppress the Ca 2+ /CaM-enhanced activity of the PI3K/Akt signaling pathway in AD cells, leading to a significant increase in the levels of the CDKi p27, and thus inhibiting cell proliferation (Fig. 10) . 15d-PGJ 2 -mediated decrease of Akt activity impaired the increased phosphorylation of p27 at Thr187 and induced the retention of p27 in the nucleus, thus decreasing the cytosolic degradation of p27 by the proteasome. /ml and cultured for 3 days in RPMI medium containing 10 % FBS. Whole cell extracts were prepared thereafter, and immunoblotted with anti-aÀCaM antibody. A representative immunoblot is shown in the inset. Band intensities were measure and normalized by that of b-actin. Statistical significance was determined by the t-test.
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Alterations in Akt activity [55] , changes in the abundance of p27 [56] , as well as changes in cyclin/ CDK activity [57] have also been detected in AD brain, suggesting that peripheral cells from patients may be a potential useful surrogate for diagnosis, prognosis and therapeutic monitoring of AD. The alteration in both cyclin/CDK activity and CDKi content seems to contribute significantly to AD pathology since abnormal cyclin/CDK activity appears to correlate with enhanced tau phosphorylation and tangle formation [57] . Moreover, phosphorylated p27 (Thr187) shows considerable overlap with taupositive neurofibrillary pathology in AD brains [58] . Although cyclopentenone prostaglandins cannot be considered inert compounds, our observation that 15d-PGJ 2 had no detectable effects in cell proliferation and signaling thought PI3K/Akt in control cells, while it is capable of selectively suppress the serummediated enhanced activation of AD cells, indicates its potential benefit in a therapeutic setting.
